Shiny Thomas

Shiny Thomas

Auto-generated profile, based on publicly available information

Shiny Thomas

New York State Department of Health Albany New York USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2016 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
STShiny Thomas
Shiny Thomas
MHMary E. Hovinga
Mary E. Hovinga
DRDheeraj Rai
Dheeraj Rai
BLBrian K Lee
Brian K Lee

11 April 2022 in Muscle & Nerve
Verified
Journal Article
Closed access
STShiny Thomas
Shiny Thomas
KCKristin Conway
Kristin Conway
OFOlushola Fapo
Olushola Fapo
NSNatalie Street
Natalie Street
KMKatherine D. Mathews
Katherine D. Mathews
ECEmma Ciafaloni
Emma Ciafaloni


30 March 2018 in Muscle & Nerve
Verified
Journal Article
Closed access
PDF file
SPShree Pandya
Shree Pandya
KJKatherine A. James
Katherine A. James
CWChristina Westfield
Christina Westfield
STShiny Thomas
Shiny Thomas
DFDeborah J. Fox
Deborah J. Fox
RMRichard T. Moxley
Richard T. Moxley

23 October 2018 in Journal of Neuromuscular Diseases
Verified
Journal Article
Closed access
PDF file
DWDavid R. Weber
David R. Weber
STShiny Thomas
Shiny Thomas
SEStephen W. Erickson
Stephen W. Erickson
DFDeborah Fox
Deborah Fox
JOJoyce Oleszek
Joyce Oleszek
RSResearch Network (MD STAR)
Research Network (MD STAR)
Background: Patients with Duchenne muscular dystrophy (DMD) are at high risk of endocrine and bone health complications resulting from the high glucocorticoid (GC) doses used to treat this condition. There are limited data characterizing the clinical

18 October 2023 in Birth Defects Research
Verified
Journal Article
Open access
KCKristin M. Conway
Kristin M. Conway
STShiny Thomas
Shiny Thomas
ECEmma Ciafaloni
Emma Ciafaloni
RKRabia S. Khan
Rabia S. Khan
JMJoshua R. Mann
Joshua R. Mann
KMKatherine D. Mathews
Katherine D. Mathews
Background: Epidemiological support for prophylactic treatment of left ventricular dysfunction (LVD) in Duchenne muscular dystrophy is limited. We used retrospective, population‐based surveillance data from the Muscular Dystrophy Surveillance, Tracking and Research Network to evaluate whether prophylaxis delays LVD onset.Methods: We analyzed 455 males born during 1982–2009. Age at first abnormal echocardiogram (ejection fraction <55% or shortening fraction <28%) determined LVD onset. Prophylaxis was defined as cardiac medication use at least 1 year prior to LVD. Corticosteroid use was also coded. Kaplan–Meier curve estimation and Cox Proportional Hazard modeling with time‐varying covariates describe associations.Results: LVD was identified among 40.7%; average onset age was 14.2 years. Prophylaxis was identified for 20.2% and corticosteroids for 57.4%. Prophylaxis showed delayed LVD onset (p < .001) and lower hazard of dysfunction (adjusted hazard ratio [aHR] = 0.39, 95%CL = 0.22, 0.65) compared to untreated. Compared to no treatment, continuous corticosteroids only (aHR = 1.01, 95%CL = 0.66, 1.53) and prophylaxis only (aHR = 0.67, 95%CL = 0.25, 1.50) were not cardioprotective, but prophylaxis plus continuous corticosteroids were associated with lower hazard of dysfunction (aHR = 0.37, 95%CL = 0.15, 0.80).Conclusions: Proactive cardiac treatment and monitoring are critical aspects of managing Duchenne muscular dystrophy. Consistent with clinical care guidelines, this study supports clinical benefit from cardiac medications initiated prior to documented LVD and suggests further benefit when combined with corticosteroids.